Pioglitazone and Losartan Provides Additional Renoprotection

Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00364988

Enrollment

Registered

2006-08-16

Start date

2005-01-31

Completion date

2006-01-31

Last updated

2014-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy, Type 2 Diabetes

Keywords

pioglitazone, losartan, proteinuria, end stage renal disease (ESRD)

Brief summary

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

Interventions

DRUGpioglitazone+losartan

Pioglitazone (30 mg/daily) losartan (100 mg daily)

DRUGlosartan

losartan (100 mg daily)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

32 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L * 2h plasma glucose level of 7.5-13 mmol/L * serum creatinine values between 190 and 660umol/L * Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg * Informed consent

Exclusion criteria

* Type1 diabetes or nondiabetic renal disease * abnormal liver function * heart dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Renal function	12 month	fasting glucose, HbA 1c , Scr, 24-hour urinary protein excretion, and endogenous creatinine clearance (Ccr)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026